A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, Oct. 24, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to...
NEW YORK, Sept. 1, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C. Wainwright 24th Annual Global Investor Conference. Delcath CEO,...
NEW YORK, Aug. 8, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30,...
Retrospective study in metastatic uveal melanoma patients with liver dominant disease shows an objective response rate of 59.4% and a disease control rate of 89.1%. The study finds that achieving complete response, partial response, or stable disease is associated...
NEW YORK, July 27, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 8, 2022, at 8:30 AM Eastern Time to...
NEW YORK, July 20, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement for the issuance and...
NEW YORK, July 18, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain...
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free survival...
NEW YORK , May 10, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31,...
NEW YORK, May 09, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the acceptance of a poster presentation at the upcoming American Society of...